These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25178969)

  • 1. The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.
    Gil L; Marcos E; Izquierdo A; Lazo L; Valdés I; Ambala P; Ochola L; Hitler R; Suzarte E; Álvarez M; Kimiti P; Ndung'u J; Kariuki T; Guzmán MG; Guillén G; Hermida L
    Immunol Cell Biol; 2015 Jan; 93(1):57-66. PubMed ID: 25178969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys.
    Suzarte E; Gil L; Valdés I; Marcos E; Lazo L; Izquierdo A; García A; López L; Álvarez M; Pérez Y; Castro J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2015 Aug; 27(8):367-79. PubMed ID: 25795768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
    Zuest R; Valdes I; Skibinski D; Lin Y; Toh YX; Chan K; Hermida L; Connolly J; Guillen G; Fink K
    Vaccine; 2015 Mar; 33(12):1474-82. PubMed ID: 25659270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses.
    Valdés I; Marcos E; Suzarte E; Pérez Y; Brown E; Lazo L; Cobas K; Yaugel M; Rodríguez Y; Gil L; Guillén G; Hermida L
    Arch Virol; 2017 Aug; 162(8):2247-2256. PubMed ID: 28393307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus.
    Marcos E; Gil L; Lazo L; Izquierdo A; Brown E; Suzarte E; Valdés I; García A; Méndez L; Guzmán MG; Guillén G; Hermida L
    Arch Virol; 2013 Jan; 158(1):225-30. PubMed ID: 22983185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
    Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
    Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation in Mice of the Immunogenicity of a Tetravalent Subunit Vaccine Candidate Against Dengue Virus Using Mucosal and Parenteral Immunization Routes.
    Lazo Vázquez L; Gil González L; Marcos López E; Pérez Fuentes Y; Cervetto de Armas L; Brown Richards E; Valdés Prado I; Suzarte Portal E; Cobas Acosta K; Yaugel Novoa M; Romero Fernández Y; Guillén Nieto G; Hermida Cruz L
    Viral Immunol; 2017 Jun; 30(5):350-358. PubMed ID: 28418786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
    Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
    Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
    García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
    Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice.
    Izquierdo A; García A; Lazo L; Gil L; Marcos E; Alvarez M; Valdés I; Hermida L; Guillén G; Guzmán MG
    Arch Virol; 2014 Oct; 159(10):2597-604. PubMed ID: 24841761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.
    Bernardo L; Izquierdo A; Alvarez M; Rosario D; Prado I; López C; Martínez R; Castro J; Santana E; Hermida L; Guillen G; Guzmán MG
    Antiviral Res; 2008 Nov; 80(2):194-9. PubMed ID: 18602424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
    Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
    Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice.
    Coconi-Linares N; Ortega-Dávila E; López-González M; García-Machorro J; García-Cordero J; Steinman RM; Cedillo-Barrón L; Gómez-Lim MA
    Vaccine; 2013 May; 31(19):2366-71. PubMed ID: 23499580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
    Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
    J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use.
    Valdés I; Hermida L; Gil L; Lazo L; Castro J; Martín J; Bernardo L; López C; Niebla O; Menéndez T; Romero Y; Sánchez J; Guzmán MG; Guillén G
    Int J Infect Dis; 2010 May; 14(5):e377-83. PubMed ID: 19773190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.
    Li XF; Deng YQ; Yang HQ; Zhao H; Jiang T; Yu XD; Li SH; Ye Q; Zhu SY; Wang HJ; Zhang Y; Ma J; Yu YX; Liu ZY; Li YH; Qin ED; Shi PY; Qin CF
    J Virol; 2013 Dec; 87(24):13694-705. PubMed ID: 24109223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins.
    Bernardo L; Hermida L; Martin J; Alvarez M; Prado I; López C; Martínez R; Rodríguez-Roche R; Zulueta A; Lazo L; Rosario D; Guillén G; Guzmán MG
    Arch Virol; 2008; 153(5):849-54. PubMed ID: 18299795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.